NewAmsterdam Pharma Announces Initial Data from Phase 2a Cli

-- Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid , respectively, indicating potential improvement of cholesterol metabolism in the brain -- -- Observed 8%...

Related Keywords

Brooklyn , Florida , United States , Netherlands , Naarden , Noord Holland , Ukraine , Russia , Miami , John Kastelein , Las Vegas , Jeffrey Cummings , Matthew Philippe , Michael Davidson , Hannah Deresiewicz , Company Phase , Grundy Center , Drug Administration , University Of Nevada , Securities Exchange Commission , Company Contact , Neither The Company , Newamsterdam Pharma Companynv Nasdaq , Chambers Grundy Center , Transformative Neuroscience , Chief Executive Officer , Chief Scientific Officer , Looking Statements , Securities Exchange , Investor Relations , Markets ,